LANSING, Mich. and BOSTON, Mass., June 16, 2026
Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic supply agreement for cGMP-grade Actinium-225 (Ac-225), strengthening the infrastructure needed to support the next generation of targeted alpha radiopharmaceutical therapies for cancer treatment. The collaboration provides Ratio Therapeutics with a reliable source of the highly sought-after radioisotope as it advances its clinical-stage pipeline of precision oncology therapies. The agreement highlights the growing importance of securing scalable and dependable isotope supplies as radiopharmaceutical development accelerates globally. With demand for Actinium-225-based targeted alpha therapies increasing across the oncology sector, the partnership is expected to support ongoing clinical trials, future development programs, and long-term commercialization efforts aimed at delivering innovative cancer treatments to patients.
Strategic Supply Agreement Supports Radiopharmaceutical Development
Actinium-225 has emerged as one of the most valuable isotopes in modern nuclear medicine because of its ability to deliver highly potent alpha radiation directly to cancer cells. When linked to tumor-targeting molecules, the isotope can selectively destroy malignant cells while minimizing damage to surrounding healthy tissue. This targeted mechanism has generated significant interest among pharmaceutical companies developing precision oncology therapies for difficult-to-treat cancers. Under the new agreement, Niowave will supply cGMP Actinium-225 to support Ratio Therapeutics’ growing portfolio of radiopharmaceutical programs.
Access to a dependable domestic isotope supply remains a critical challenge for the industry, as global demand continues to outpace production capacity. By securing additional Actinium-225 resources through Niowave, Ratio is strengthening its ability to maintain clinical development timelines while ensuring sufficient isotope availability for future therapeutic applications. The collaboration reflects a broader industry trend focused on building resilient supply chains capable of supporting the expanding radiopharmaceutical ecosystem.
Actinium-225 Plays Central Role in Next-Generation Cancer Therapies
Advertisement
Targeted alpha therapies are increasingly viewed as one of the most promising areas in precision oncology due to their ability to deliver highly localized radiation with exceptional potency. Unlike conventional radiotherapy, which exposes larger tissue areas to radiation, alpha-emitting isotopes such as Actinium-225 release high-energy particles over extremely short distances, enabling precise tumor cell destruction. This approach has demonstrated significant potential across multiple cancer types and continues to attract substantial investment throughout the biopharmaceutical sector. Niowave has established itself as a leading producer of medical radioisotopes through its expertise in superconducting electron linear accelerator technology and advanced radiochemistry processes.
The company’s expanding production capabilities are helping address one of the key bottlenecks facing targeted alpha therapy development. For Ratio Therapeutics, reliable isotope access supports its mission of advancing innovative radiopharmaceutical candidates designed to improve tumor targeting, enhance therapeutic effectiveness, and expand treatment options for patients with solid tumors.
Expanding Infrastructure for Precision Oncology Innovation
The agreement also reinforces the importance of manufacturing readiness and strategic partnerships in the rapidly growing radiopharmaceutical market. Ratio Therapeutics continues to advance a portfolio of precision radiopharmaceuticals built on its proprietary Trillium™ and Macropa™ technology platforms, which are designed to optimize pharmacokinetics, improve tumor delivery, and enhance therapeutic performance. At the same time, Niowave remains focused on expanding domestic production of critical medical isotopes to support increasing clinical and commercial demand.
Industry experts view reliable isotope availability as essential to unlocking the full potential of targeted alpha therapies, particularly as more candidates enter late-stage clinical development. By combining Niowave’s isotope manufacturing expertise with Ratio’s innovative radiopharmaceutical pipeline, the collaboration strengthens the foundation for future advances in cancer treatment. As targeted radiotherapies continue to reshape oncology care, strategic supply agreements such as this one will play a vital role in ensuring that promising therapies can move efficiently from clinical development to broader patient access.
Source: Niowave, Ratio Therapeutics press release
